medigraphic.com
ISSN 1561-302X (Impreso)

2021, Número 2

<< Anterior Siguiente >>

Rev cubana med 2021; 60 (2)


Trasplante autólogo de progenitores hematopoyéticos en el Linfoma de Hodgkin

Hernández CC, Carnot UJ, de la Campa JD, Muñío PJ, Pardo RIK, Cepero LK, García GA

Idioma: Español
Referencias bibliográficas: 31
Paginas: 1-10
Archivo PDF: 380.70 Kb.


RESUMEN

Introducción: El trasplante autólogo de progenitores hematopoyéticos es una terapéutica aplicable en determinadas situaciones a pacientes con Linfoma de Hodgkin.
Objetivo: Evaluar la respuesta al trasplante autólogo de progenitores hematopoyéticos en los pacientes con Linfoma de Hodgkin.
Métodos: Se realizó un estudio de 60 pacientes con Linfoma de Hodgkin trasplantados en el Hospital Clínico Quirúrgico “Hermanos Ameijeiras”, entre 1991 y 2018. Se estimó el porcentaje de respuesta a los tres meses, la supervivencia global y la supervivencia libre de enfermedad a los cinco años.
Resultados: La tasa de respuesta a los tres meses fue de 82,7 %. La supervivencia global y libre de enfermedad a los cinco años fue de 94,7 % y 51,7 %, respectivamente. La mortalidad temprana relacionada con el trasplante fue de 5 %.
Conclusiones: La aplicación del trasplante autólogo de progenitores hematopoyéticos constituyó una alternativa terapéutica válida. La baja mortalidad temprana evidenció una realización del procedimiento con un perfil de seguridad satisfactorio.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Eichenauer DA, Engert A, Diehl V. Hodgkin Lymphoma: Clinical manifestations, staging, and therapy. En: Hoffman R, Benz EJ, Silberstein LE, et al. Hematology. Basic Principles and Practice. 6ta ed. Philadelphia: Elsevier Saunders; 2013.p.1138-56.

  2. Diehl V, Thomas RK, Re D. Part II: Hodgkin's lymphoma-diagnosis and treatment. Lancet Oncol. 2004;5(1):19-26. https://doi.org/10.1016/S1470-2045(03)01320-2

  3. Shanbhag S, Richard F Ambinder RF. Hodgkin lymphoma: A review and update on recent progress. CA Cancer J Clin. 2018;68(2):116-32. https://doi.org/10.3322/caac.21438

  4. Ansell SM. Hodgkin lymphoma: 2018 update on diagnosis, risk-stratification, and management. Am J Hematol 2018;93(5):704-15. https://doi.org/10.1002/ajh.25071

  5. Constine LS, Yahalom J, Ng AK, Hodgson DC, Wirth A, Milgrom SA, et al. Hodgkin Lymphoma: Guidelines From the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys. 2018;100(5):1100-18. https://doi.org/10.1016/j.ijrobp.2018.01.011

  6. Rossi C, Bastie JN. New therapeutic strategies in non-Hodgkin lymphomas and Hodgkin lymphoma. Rev Med Intern. 2019;40(4):246-54. https://doi.org/10.1016/j.revmed.2018.04.015

  7. Eichenauer DA, Aleman BMP, André M, Federico M, Hutchings M, Illidge T, et al. ESMO Guidelines Committee. Ann Oncol. 2018;29(4):19-29. https://doi.org/10.1093/annonc/mdy080

  8. Broccoli A, Zinzani PL. The role of transplantation in Hodgkin lymphoma. Br J Haematol. 2019;184(1):93-104. https://doi.org/10.1111/bjh.15639

  9. Vassilakopoulos TP, Asimakopoulos JV, Konstantopoulos K, Angelopoulou MK. Optimizing outcomes in relapsed/refractory Hodgkin lymphoma: a review of current and forthcoming therapeutic strategies. Ther Adv Hematol. 2020;11:1-31. https://doi.org/10.1177/2040620720902911

  10. Thomas ED, Storb R, Clift RA, Fefer A, Johnson L, Neiman PE, et al. Bone-marrow transplantation. N Engl J Med. 1975;292(16):832-902. https://doi.org/10.1056/NEJM197504172921605

  11. Jantunen E, Itälä M, Lehtinen T, Kuittinen O, Koivunen E, Leppä S, et al. Early treatment-related mortality in adult autologous stem cell transplant recipients: a nation-wide survey of 1482 transplanted patients. Eur J Haematol. 2006;76(3):245-50. https://doi.org/10.1111/j.1600-0609.2005.00605.x

  12. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375-90. https://doi.org/10.1182/blood-2016-01-643569

  13. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res. 1971;31(11):1860-1.

  14. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. The International Harmonization Project for response criteria in lymphoma clinical trials. Hematol Oncol Clin North Am. 2007;21(5):841-54. https://doi.org/10.1016/j.hoc.2007.06.011

  15. Carnot J, Travieso J, Muñio J, Rodríguez I. Progresos y problemas en el trasplante de médula ósea. Rev Acta Med. 1987;1:180-214.

  16. Ruiz Argüelles GJ, Lobato Mendizábal E, Ruiz Argüelles A, Pérez Romano B, Arizpe Bravo D, Marín López A. Non-cryopreserved unmanipulated hematopoietic peripheral blood stem cell autotransplant program: long term results. Arch Med Res. 1999;30(5):380-4. https://doi.org/10.1016/S0188-0128(99)00042-1

  17. Kaplan EL, Meier P. Non-parametric estimations from incomplete observations. J Am Stat Assoc. 1958;53:457.

  18. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, revised 4th edition, Swerdlow SH, Campo E, Harris NL, et al. (Eds), International Agency for Research on Cancer. (IARC), Lyon 2017.

  19. Stein RS, Morgan DS. Hodgkin Lymphoma. En: Greer JP, Foerster J, Rodgers GM, et al. Wintrobe's Clinical Hematology. 12ma Ed. Philadelphia: Lippincott Williams & Wilkins; 2009.p. 2311-42.

  20. Sirohi B, Cunningham D, Powles R, Murphy F, Arkenau T, Norman A, et al. Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma. Ann Oncol. 2008;19(7):1312-9. https://doi.org/10.1093/annonc/mdn052

  21. Fatobene G, Linardi CDCG, Moreira F, GMF Targueta, Santos FM, Velasques RD. Reassessment of risk factors and long-term results of autologous stem cell transplantation in relapsed and refractory classical Hodgkin lymphoma. Hematol Oncol. 2019;37(3):310-3. https://doi.org/10.1002/hon.2604

  22. Zahid U, Akbar F, Amaraneni A, Chan O, Riaz IB, McBride A, et al. A Review of Autologous Stem Cell Transplantation in Lymphoma. Curr Hematol Malig Rep. 2017;12(3):217-26. https://doi.org/10.1007/s11899-017-0382-1

  23. Linch DC, Winfield D, Goldstone AH, Moir D, Hancock B, McMillan A, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: Results of a BNLI randomised trial. Lancet. 1993;341(8852):1051-4. https://doi.org/10.1016/0140-6736(93)92411-L

  24. Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: A randomised trial. Lancet. 2002;359(9323):2065-71. https://doi.org/10.1016/S0140-6736(02)08938-9

  25. Lavoie JC, Connors JM, Phillips GL, Reece DE, Barnett MJ, Forrest DL, et al. High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: Long-term outcome in the first 100 patients treated in Vancouver. Blood. 2005;106(4):1473-8. https://doi.org/10.1182/blood-2004-12-4689

  26. Smith SD, Moskowitz CH, Dean R, Pohlman B, Sobecks R, Copelan E, et al. Autologous stem cell transplant for early relapsed/refractory Hodgkin lymphoma: results from two transplant centres. Br J Haematol. 2011;153(3):358-63. https://doi.org/10.1111/j.1365-2141.2011.08616.x

  27. Cortez-Afonso JP, Dulley-Frederico L, Saboya R, Mendrone-Júnior A, Amigo-Filho U, Coracin-Fabio L, et al. Autologous hematopoietic stem cell transplantation in classical Hodgkin's lymphoma. Rev Bras Hematol Hemoter. 2011;33(1):10-4. https://doi.org/10.5581/1516-8484.20110007

  28. Roerden M, Sökler M, Kanz L, Bethge W, Vogel W, Walz JS. Outcome after autologous stem cell transplantation in primary refractory or relapsed Hodgkin lymphoma-a long-term follow-up single center experience. Ann Hematol. 2020;99(2):265-76. https://doi.org/10.1007/s00277-019-03900-x

  29. Nademanee A, O'Donnell MR, Snyder D, Schmidt GM, Parker PM, Stein AS, et al. High-dose chemotherapy with or without total body irradiation followed by autologous bone marrow and/or peripheral blood stem cell transplantation for patients with relapsed and refractory Hodgkin's disease: Results in 85 patients with analysis of prognostic factors. Blood. 1995;85(5):1381-90. https://doi.org/10.1182/blood.V85.5.1381.bloodjournal8551381

  30. Sureda A, Arranz R, Iriondo A, Carreras E, Lahuerta JJ, García Conde J, et al. Autologous stem-cell transplantation for Hodgkin's disease: Results and prognostic factors in 494 patients from the Grupo Español de Linfomas/Transplante Autológo de Médula Osea Spanish Cooperative Group. J Clin Oncol. 2001;19(5):1395-404. https://doi.org/10.1200/JCO.2001.19.5.1395

  31. Styczynski J, Tridello G, Koster L, Lacobelli S, van Biezen A, van der Werf S, et al. Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors. Bone Marrow Transplant. 2020;55(1):126-36. https://doi.org/10.1038/s41409-019-0624-z




2020     |     www.medigraphic.com